Analyst Price Targets — ACB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 11, 2023 3:01 pm | EBITDA Q3 | Piper Sandler | $1.00 | $0.88 | Pulse 2.0 | Aurora Cannabis Stock Receives A $1 Price Target (ACB) |
| May 28, 2021 12:00 am | Heather Balsky | Bank of America Securities | $8.75 | $9.66 | StreetInsider | BofA Securities Reiterates Neutral Rating on Aurora Cannabis Inc. (ACB:CN) (ACB) |
| May 14, 2021 12:00 am | Tamy Chen | BMO Capital | $8.00 | $6.86 | TheFly | Aurora Cannabis upgraded to Market Perform from Underperform at BMO Capital |
This site can’t be displayed in an embedded view
Some publishers block loading inside other sites for security reasons. You can open the article in a new tab instead.
Latest News for ACB

Aurora Cannabis' shares plunge 28% in three months as a cautious fiscal 2027 outlook overshadows record medical cannabis growth and global expansion.

NASDAQ | TSX: ACB The Company makes history as the first and only cannabis company to ever receive this recognition EDMONTON, AB, July 9, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) ("Aurora" or the "Company"), the Canadian-based leading global medical cannabis company, has been awarded on TIME Canada's Best Companies 2026 list. This win reflects the Company's differentiated performance and…

Shareholders are encouraged to keep an eye out for their meeting materials and vote early – every vote matters, no matter how many shares you own. Shareholders who have questions or need assistance with voting their shares voting should contact Aurora's strategic advisor and proxy solicitation agent, Kingsdale Advisors by telephone at 1-800-749-9052 or by email at contactus@kingsdaleadvisors.com or visit…

ACB frames fiscal 2027 as a reset year as Canadian reimbursement pressure weighs on margins, even as global medical cannabis growth continues.

Aurora Cannabis reported Q4/FY2026 results largely in line with expectations previously outlined by management. In recent months, the company has made the strategic decision to exit its lower margin consumer cannabis and plant propagation operations and focus on the growing European medical cannabis market. However, FY2027 will be impacted by adverse regulatory changes in the Canadian medical cannabis market. As a…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ACB.
Senate Trading
No Senate trades found for ACB.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain Settings
Changes apply instantly as you toggle. Tap Done when finished.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.
